Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Why Big Oil Is Ditching Biotechnology

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

Landing partners with deep pockets will be critical for many developmental stage biotechnology companies looking to take their disruptive platforms to the next level. We're not talking measly partnerships here (although those are important too). We're talking major investments. Unfortunately, the prospects for megadeals have taken a hit over the last year. Several well-established energy companies have dropped or distanced themselves from the list of financiers for budding industrial biotechnology companies.

Big oil isn't abandoning renewable technologies altogether, but many companies have pivoted their focus away from genome hacking and toward more familiar industrial technology. While funding hasn't necessarily dried up, the nascent industrial biotechnology industry could sure use a little more confidence from global energy leaders. With all of the potential behind bio-based chemicals investors may be left wondering: "What gives?"

Brute force vs. finesse
The oil and chemical industries are dominated by thermocatalytic processes, or those that use high heat and pressure to drive chemical reactions and produce useful products. This is the "brute force" approach. Industrial biotechnology, which utilizes biocatalytic processes, sits at the other end of the spectrum. These platforms use biological pathways in microbial cells -- bacterial, fungal, viral, mammalian, floral, and algal -- to turn chemical feedstocks into useful chemicals. This is the finesse approach.  

A general lack of understanding of how cells interact with genetic tweaking, the shear forces inside a massive bioreactor, and other industrial variables is the biggest problem facing biocatalytic technology. That makes using the methane and ethane found in natural gas as chemical feedstocks a pretty sexy idea. Nat-gas is cheap and the processes involved -- or those very similar to it -- have been commercially viable since World War 2.

The shorter list of unknowns for thermocatalytic technologies makes returns more certain, which is an important factor to consider when writing eight-figure checks. It also doesn't help that the massive amounts of natural gas beneath our feet are currently much easier to access than the cellulosic sugars in agricultural wastes. Much like us individual investors, big oil is seeking to mitigate risks and maintain a clearer picture on their potential returns.

A zero-sum game?
(NYSE: VLO  ) was the first major refiner to get into the ethanol business and now owns 10 refineries. The company has kept a broad focus with its renewable energy portfolio, although the largest investments are in thermocatalytic companies such as Enerkem and several ventures producing biodiesel. Valero's small partnership with algae fuels company Algenol shows that while the company acknowledges the potential, it is still hesitant about throwing much weight behind more advanced biotechnology ideas. The rest of the industry isn't much different.

Early last year Shell (NYSE: RDS-A  ) quietly announced that it had built a drop-in biofuels facility using a thermocatalytic process licensed from partner Virent. It proceeded to cut direct ties with industrial bioenzyme manufacturers Iogen and Codexis (NASDAQ: CDXS  ) , which many people believed were the front-runners for the company's plans in biofuels.

BP (NYSE: BP  ) followed suit in October by canning a cellulosic ethanol plant in Florida. The biorefinery was expected to utilize biocatalytic technology from Verenium, but decided to use the money on "more attractive investments". BP is still developing the technology, but plans to license it out to willing participants from now on. It is, however, the leading energy company backing Cool Planet Energy Systems, a developmental stage company building a modular thermocatalytic platform to produce carbon negative fuels from biomass.

ExxonMobil (NYSE: XOM  ) went all-in on developing algae technology with Dr. J. Craig Venter's Synthetic Genomics. A (brace yourself) nearly $600 million investment exploring the possibilities of industrial biotechnology's holy grail turned sour earlier this year as the companies stated that the technology they were trying to develop is "probably further than 25 years away". Ouch.  

Foolish bottom line
When some of the biggest names in energy have less-than-stellar news to report about industrial biotechnology, it is easy to see why many investors are down on the industry. On one hand, you have to admire their efforts and acknowledge that they are making the safer investments. On the other hand, you could accuse them of being too focused on the short term.

Bio-based fuels and chemicals are stuck in a catch-22. The technologies need more funding to develop, but aren't attracting funding because they need to develop. One day soon these sustainable petroleum alternatives will make it to the market. Hoping to catch the wave by investing in big oil companies may not be your best bet.

If you want to follow big oil in your investing -- a pretty good idea -- check out The Motley Fool's "3 Stocks for $100 Oil." For FREE access to this special report, simply click here now.


Read/Post Comments (2) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On March 29, 2013, at 9:55 AM, PEStudent wrote:

    As a former industrial organic R & D Chemist, I resent the "brute force vs finesse" statement in the article. It displays ignorance of the processes involved. The so-call biotech "finesse" is currently too slow to allow large production at reasonable costs. The so-called chemical "brute force" involves a lot of "finesse involving combinations of catalysts and temperatures and pressures, etc. fitted to the type of crude oil being processed. That's a lot of "finesse."

    Believe me, if biotech seems likely to offer a way to produce products for less expense, industry will jump on it. Hopefully, that day will come but it's not here yet.

  • Report this Comment On March 29, 2013, at 10:18 AM, TMFBlacknGold wrote:


    There's always finesse involved in chemical reactions, thermo or bio. Brute force certainly applies to thermocatalytic processes such as pyrolysis before it applies to biological pathway manipulation. I have a counter article set to publish this weekend.


Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2337072, ~/Articles/ArticleHandler.aspx, 9/28/2016 6:21:31 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,339.24 110.94 0.61%
S&P 500 2,171.37 11.44 0.53%
NASD 5,318.55 12.84 0.24%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/28/2016 4:00 PM
BP $34.84 Up +1.23 +3.66%
BP CAPS Rating: ****
CDXS $4.41 Up +0.09 +2.08%
Codexis CAPS Rating: **
RDS-A $48.72 Up +1.62 +3.44%
Royal Dutch Shell… CAPS Rating: ****
VLO $55.11 Up +0.09 +0.16%
Valero Energy CAPS Rating: ****
XOM $86.90 Up +3.66 +4.40%
ExxonMobil CAPS Rating: ****